Results 171 to 180 of about 3,168 (197)

Romosozumab and antiresorptive treatment: the importance of treatment sequence

Osteoporosis International, 2022
Felicia Cosman, David L Kendler, Bente L Langdahl   +2 more
exaly  

Effect of the duration of previous osteoporosis treatment on the effect of romosozumab treatment

Osteoporosis International, 2022
Wada K
exaly  

Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis

Joint Bone Spine, 2021
Kosuke Ebina, Yoshio Nagayama, Masafumi Kashii   +2 more
exaly  

A systematic review and meta-analysis of efficacy and safety of Romosozumab in postmenopausal osteoporosis

Osteoporosis International, 2021
Siddhartha Dutta, Sameer Khasbage, Tarun Kumar   +2 more
exaly  

Evaluation of Risk of Cardiac or Cerebrovascular Events in Romosozumab Users Focusing on Comorbidities: Analysis of the Japanese Adverse Drug Event Report Database

Journal of Pharmacy Technology, 2023
Kazumasa Kotake, Satoru Mitsuboshi
exaly  

Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study

Journal of Bone and Mineral Metabolism, 2021
Shinsuke Yamada, Masanori Emoto, Yoshiteru Ohno   +2 more
exaly  

Romosozumab: A Novel Agent in the Treatment for Postmenopausal Osteoporosis

Journal of Pharmacy Technology, 2021
Shannon A Miller, Erin St Onge
exaly  

Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS)

Journal of Clinical Medicine, 2021
Junaid Faruque, Enriqueta Vallejo-Yagüe, Stefan Weiler   +2 more
exaly  

Romosozumab and Renal Function

Journal of Bone and Mineral Research, 2020
openaire   +2 more sources

A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab

Osteoporosis International, 2020
Michael R Mcclung, Jacques P Brown, Bente L Langdahl   +2 more
exaly